DataSheet_1_Prognostic Value of Leucocyte to High-Density Lipoprotein-Cholesterol Ratios in COVID-19 Patients and the Diabetes Subgroup.docx by Yuxiu Wang (8088287)

“…</p>Methods<p>We conducted a multicenter retrospective cohort study involving all hospitalized patients with COVID-19 from January to March 2020 in five hospitals in Wuhan, China. …”

Image_1_T-Lymphocyte Subsets Alteration, Infection and Renal Outcome in Advanced Chronic Kidney Disease.TIF by Jiachuan Xiong (748476)

“…The primary outcomes were the major infection and renal outcome.</p><p>Results: A total of 410 CKD patients were enrolled; the average age was 47.25 years. …”

DataSheet_1_Dysregulation of iron metabolism modulators in virologically suppressed HIV-infected patients.docx by Vanesa Garrido-Rodríguez (14172573)

“…Since virologically suppressed chronic HIV-infected subjects under effective antiretroviral treatment (ART) exhibit a persistent immune dysfunction that leads to comorbidities, iron homeostasis may be relevant in this context. …”

datasheet1_Spatio-Temporal Variability of Peat CH4 and N2O Fluxes and Their Contribution to Peat GHG Budgets in Indonesian Forests and Oil Palm Plantations.docx by Erin Swails (10323518)

“…The objective of our research was to assess changes in peat GHG flux and budget associated with peat swamp forest disturbance and conversion to oil palm plantation and to evaluate drivers of variation in trace gas fluxes. Over a period of one and a half year, we monitored monthly CH₄ and N₂O fluxes together with environmental variables in three undrained peat swamp forests and three oil palm plantations on peat in Central Kalimantan. …”

Data_Sheet_1_T-Lymphocyte Subsets Alteration, Infection and Renal Outcome in Advanced Chronic Kidney Disease.docx by Jiachuan Xiong (748476)

“…The primary outcomes were the major infection and renal outcome.</p><p>Results: A total of 410 CKD patients were enrolled; the average age was 47.25 years. …”

Image_2_T-Lymphocyte Subsets Alteration, Infection and Renal Outcome in Advanced Chronic Kidney Disease.TIFF by Jiachuan Xiong (748476)

“…The primary outcomes were the major infection and renal outcome.</p><p>Results: A total of 410 CKD patients were enrolled; the average age was 47.25 years. …”

Northern blot analysis of riRNA. by Hiraku Takada (3599702)

“…The level of rRNA markedly decreased in the stationary phase. [C] <i>E</i>. <i>coli</i> BW25113 was grown in M9-glucose medium, and in the middle of exponential phase, total RNA was prepared using Isogen and subjected to Northern blot analysis using a series of Northern probes (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0163057#pone.0163057.t001" target="_blank">Table 1</a>, probes N01 to N10). riRNA was detected using two specific probes, probe-N3 and probe-N4 (for probes see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0163057#pone.0163057.t001" target="_blank">Table 1</a>; and for primers used for amplification of these probes, see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0163057#pone.0163057.s005" target="_blank">S2 Table</a>). …”

Supplemental Material for Juurakko et al., 2021 by Collin L. Juurakko (10941459)

“…</p><p></p><p></p><p> </p><p>A list of protein accession identifications for all significantly increased and decreased proteins obtained by MS were assembled and used as inputs for STRING (version 11.0) to predict protein-protein interactions (Franceschini <i>et al.…”

Robotic-Assisted Median Arcuate Ligament Release With Celiac Artery Lysis and Celiac Ganglion Neurolysis by G. Kimble Jett (6509428)

“…<a href="https://doi.org/10.1016/j.jvs.2008.12.078"><em>J Vasc Surg</em>. 2009;50:124-133.…”

Table_8_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.XLSX by Huiling Zheng (49699)

“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”

Table_1_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”

Table_6_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”

Table_10_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”

Table_2_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.XLSX by Huiling Zheng (49699)

“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”

P4HA3 deficiency increased sensitization to immune checkpoint inhibitors and P4HA3 could predict the clinical therapeutic effect of PD-1 inhibitor (Camrelizumab). by Hong Yan Huang (20135965)

“…(B) P4HA3 deficiency inhibited proliferation ability of MDA-MB-231, HCT116 and A549 cell lines by EdU assay. Scale bar: 50 μm. …”

Table_7_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”

Table_13_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”

Table_12_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”

Living 3,4-Polymerization of Isoprene by Cationic Rare Earth Metal Alkyl Complexes Bearing Iminoamido Ligands by Gaixia Du (1631482)

“…The sterically crowded complexes <b>1</b>−<b>3</b> give a mixture of 3,4- and <i>trans</i>-1,4-polyisoprenes (3,4-selectivities: 48−82%, <i>trans</i>-1,4-selectivities: 50−17%), whereas the less sterically demanding complexes <b>4</b>−<b>6</b> show high 3,4-selectivities (3,4-selectivities: 90−100%). …”

DataSheet1_Insights into the reactivity and lithium plating mechanisms of ultra-thin metal oxide coatings for anode-free solid-state lithium metal batteries.docx by Michael J. Counihan (4852780)

“…Increasing Al₂O₃ thickness decreases the practical current density compared to unmodified Cu (30 µA/cm²), but increasing ZnO thicknesses can double or triple this value. …”